aA patient whom the site intended to report as a screening failure was inadvertently entered into the computerized randomization system. This patient was excluded from the full analysis set.
eAppendix. Supplemental Methods
eFigure. Correlation Between Change in NTproBNP and Ventricular Volumes/KCCQ
eTable. Adverse Events, by Treatment
Statistical Analysis Plan
Data Sharing Statement
Customize your JAMA Network experience by selecting one or more topics from the list below.
Desai AS, Solomon SD, Shah AM, et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019;322(11):1077–1084. doi:10.1001/jama.2019.12843
What pathophysiologic mechanisms contribute to the clinical effects of sacubitril-valsartan compared with enalapril in patients with heart failure and reduced ejection fraction (HFrEF)?
In this randomized clinical trial of 464 participants with HFrEF, there was no significant difference in the change in aortic characteristic impedance (a measure of central aortic stiffness) at 12 weeks among patients treated with sacubitril-valsartan vs enalapril (−2.9 vs −0.7 dyne × s/cm5).
Treatment of HFrEF with sacubitril-valsartan, compared with enalapril, did not significantly reduce central aortic stiffness.
Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling.
To determine whether treatment of HFrEF with sacubitril-valsartan improves central aortic stiffness and cardiac remodeling compared with enalapril.
Design, Setting, and Participants
Randomized, double-blind clinical trial of 464 participants with heart failure and ejection fraction of 40% or less enrolled across 85 US sites between August 17, 2016, and June 28, 2018. Follow-up was completed on January 26, 2019.
Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks.
Main Outcomes and Measures
The primary outcome was change from baseline to week 12 in aortic characteristic impedance (Zc), a measure of central aortic stiffness. Prespecified secondary outcomes included change from baseline to week 12 in N-terminal pro–B-type natriuretic peptide, ejection fraction, global longitudinal strain, mitral annular relaxation velocity, mitral E/e′ ratio, left ventricular end-systolic and end-diastolic volume indexes (LVESVI and LVEDVI), left atrial volume index, and ventricular-vascular coupling ratio.
Of 464 validly randomized participants (mean age, 67.3 [SD, 9.1] years; 23.5% women), 427 completed the study. At 12 weeks, Zc decreased from 223.8 to 218.9 dyne × s/cm5 in the sacubitril-valsartan group and increased from 213.2 to 214.4 dyne × s/cm5 in the enalapril group (treatment difference, −2.2 [95% CI, −17.6 to 13.2] dyne × s/cm5; P = .78). Of 9 prespecified secondary end points, no significant between-group difference in change from baseline was seen in 4, including left ventricular ejection fraction (34%-36% with sacubitril-valsartan vs 33 to 35% with enalapril; treatment difference, 0.6% [95% CI, −0.4% to 1.7%]; P = .24). However, greater reductions from baseline were seen with sacubitril-valsartan than with enalapril in all others, including left atrial volume (from 30.4 mL/m2 to 28.2 mL/m2 vs from 29.8 mL/m2 to 30.5 mL/m2; treatment difference, −2.8 mL/m2 [95% CI, −4.0 to −1.6 mL/m2]; P < .001), LVEDVI (from 75.1 mL/m2 to 70.3 mL/m2 vs from 79.1 mL/m2 to 75.6 mL/m2; treatment difference, −2.0 mL/m2 [95% CI, −3.7 to 0.3 mL/m2]; P = .02), LVESVI (from 50.8 mL/m2 to 46.3 mL/m2 vs from 54.1 to 50.6 mL/m2; treatment difference, −1.6 mL/m2 [95% CI, −3.1 to −0.03 mL/m2]; P = .045), and mitral E/e′ ratio (from 13.8 to 12.3 vs from 13.4 to 13.8; treatment difference, −1.8 [95% CI, −2.8 to −0.8]; P = .001). Rates of adverse events including hypotension (1.7% vs 3.9%) were similar in both groups.
Conclusions and Relevance
Treatment of HFrEF with sacubitril-valsartan, compared with enalapril, did not significantly reduce central aortic stiffness. The study findings may provide insight into mechanisms underlying the effects of sacubitril-valsartan in HFrEF.
ClinicalTrials.gov Identifier: NCT02874794
Among patients with heart failure and reduced ejection fraction (HFrEF) enrolled in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial,1 angiotensin receptor–neprilysin inhibition (ARNI) with sacubitril-valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to angiotensin-converting enzyme (ACE) inhibition with enalapril. The benefits of sacubitril-valsartan were apparent early after randomization, consistent across all examined subgroups, and unrelated to differential changes in blood pressure over the course of the trial.1,2 Treatment guidelines have been updated to encourage substitution of ARNI for ACE inhibitors/angiotensin receptor blockers (ARBs) in patients with symptomatic HFrEF.3
Quiz Ref IDThe pathophysiologic mechanisms responsible for benefits of ARNI over ACE inhibition remain unclear. Neprilysin inhibition enhances circulating levels of biologically active natriuretic peptides and other vasoactive peptides that may have favorable vasodilatory, antifibrotic, and antihypertrophic effects. In hypertension, neprilysin inhibition reduces central aortic impedance, a key determinant of ventricular load and cardiac performance.4,5 Rapid reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) and biomarkers of collagen turnover during treatment of HFrEF with sacubitril-valsartan are consistent with a direct effect of neprilysin inhibition on ventricular wall stress and cardiovascular structure and function.6 This article summarizes the principal results of a randomized, multicenter trial to examine the effect of sacubitril-valsartan compared with enalapril on central aortic stiffness and cardiac remodeling in patients with HFrEF.
EVALUATE-HF was a multicenter randomized trial conducted at 85 hospital and clinic-based study sites in the United States. The study protocol (Supplement 1) was approved by the institutional review board or ethics committee at each site prior to enrollment of the first participant, and all participants provided written informed consent.
Quiz Ref IDKey criteria for study eligibility included age 50 years or older; history of hypertension; chronic heart failure with left ventricular ejection fraction of 40% or less; New York Heart Association class I, II, or III symptoms; and treatment with stable doses of guideline-directed medical therapy other than ACE inhibitors or ARBs with systolic blood pressure greater than 105 mm Hg at both screening and randomization.
Key exclusion criteria included current or prior treatment with sacubitril-valsartan; persistent or permanent atrial fibrillation at screening or randomization; and inability to secure a technically adequate baseline hemodynamic study. Detailed eligibility criteria are summarized in the eAppendix in Supplement 2.
Participants meeting all eligibility criteria during screening were randomized in a 1:1 fashion to double-blind, double-dummy treatment with sacubitril-valsartan (initial dosage, 24/26 mg twice daily titrated to a target dosage of 97/103 mg twice daily) plus enalapril placebo or enalapril (initial dosage, 2.5 mg twice daily, titrated to a target dosage of 10 mg twice daily) plus sacubitril-valsartan placebo using a computerized permuted-block randomization system (block size of 4) with concealed study group assignments. Patients taking an ACE inhibitor prior to study enrollment underwent 36-hour washout prior to randomization. Because recruitment of participants from racial and ethnic minorities was a goal, race was ascertained at the time of randomization by patient self-report according to predefined study categories. At week 12, all participants were transitioned to open-label sacubitril-valsartan after a 36-hour washout of blinded study drug. Longer duration of randomized follow-up was thought to be unethical in light of the established clinical superiority of sacubitril-valsartan. Details of study drug dosing and titration are further elaborated in the eAppendix in Supplement 2.
Hemodynamic data were acquired using arterial applanation tonometry and echocardiography at baseline, week 4, week 12, and week 24, as previously described.7 All data were digitized during the primary acquisition and transferred to the hemodynamic core laboratory (Cardiovascular Engineering Inc, Norwood, Massachusetts) for analysis by personnel blinded to treatment assignment. Aortic characteristic impedance (Zc), a measure of central aortic stiffness and a key determinant of ventricular wall stress,8 was calculated as the ratio of change in carotid pressure (derived from carotid tonometry waveform) and the change in flow in the proximal aorta (derived from Doppler echocardiography of the left ventricular outflow tract) during early systole. Higher values of Zc represent greater stiffness and ventricular load, and the reference value for a 70-year-old man is 250 dyne × s/cm5.7 Additional details regarding acquisition and analysis of hemodynamic data are provided in the eAppendix in Supplement 2.
Cardiac structure and function were assessed by 2-dimensional echocardiography during screening, week 4, week 12, and week 24. Parameters prespecified in the statistical analysis plan (Supplement 3) included left ventricular ejection fraction, indexed left ventricular end-systolic and end-diastolic volumes, indexed left atrial volume, lateral early diastolic mitral annular velocity (e′), ratio of mitral peak velocity of early filling (E) to e′, ratio of arterial to end-systolic elastance (Ea/Ees), and global longitudinal strain. Echocardiograms were obtained at study sites according to a standardized protocol and transmitted to the cardiac imaging core laboratory, where they were reviewed in blinded fashion according to American Society of Echocardiography standards (eAppendix in Supplement 2).
Cardiac biomarkers including NT-proBNP, high-sensitivity troponin T, soluble ST2 (a member of the interleukin 1 receptor family expressed by cells in response to myocardial stress), and urinary cyclic guanosine monophosphate/urinary creatinine ratio were analyzed in a central laboratory (eAppendix in Supplement 2) using stored samples collected prior to study drug administration at randomization and at 2, 4, 12, and 24 weeks.
The primary study end point was the between-group difference in change in Zc from baseline to week 12. Prespecified secondary end points included differences between groups in change from baseline to week 12 in NT-proBNP as well as change from baseline to week 12 in left ventricular ejection fraction, global longitudinal strain, left atrial volume index, e′ velocity, mitral E/e′ ratio, left ventricular end-systolic and end-diastolic volume indices, and Ea/Ees ratio. An analysis of the effect of treatment on correlation between change in NT-proBNP and change in Zc at 4 weeks was prespecified but not performed because of a lack of observed change in Zc at that time point. Exploratory end points of interest included difference between groups in change from baseline to week 12 in high-sensitivity troponin T, ST2, and urinary cyclic guanosine monophosphate/urinary creatinine ratio, change from baseline in central and brachial blood pressure and pulse pressure, as well as change from baseline in the overall summary score of the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ), a 0- to 100-point scale in which higher scores represent fewer symptoms and physical limitations due to heart failure.9 Because a change of 5 points or greater on the KCCQ is generally accepted to be clinically meaningful,10 we assessed the proportion of patients achieving this threshold by treatment group in post hoc analyses.
Assuming a clinically important change in Zc of 30 dyne × s/cm5 from baseline to week 12 (based on data from the CHOIR study4), a standard deviation of change in Zc of 80 dyne × s/cm5, a 20% rate of study dropout, a 10% rate of nonevaluable tonometry data, and a 2-sided α = .05, we estimated that a sample size of 432 patients (216 per group) would provide 90% power for the primary end point.
Analyses of the change from baseline in all primary and secondary echocardiographic end points was performed using an analysis-of-covariance model adjusted for baseline values and treatment assignment without imputation for missing values. Because of the potential for type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as hypothesis-generating. For cardiac biomarkers, proportional change from baseline is expressed as a ratio of geometric means and was analyzed using an analysis-of-covariance model adjusted for baseline values. For the KCCQ, change from baseline in the overall summary score and component scores was analyzed based on a repeated-measures analysis-of-covariance model in which treatment, week, and treatment × week interaction were included as fixed-effect factors and baseline value as a covariate, with a common unstructured covariance for each treatment group. In post hoc analyses, change from baseline in brachial and central blood pressure was analyzed in analysis-of-covariance models adjusted for baseline values. In addition, correlations between changes in echocardiographic parameters, biomarkers, and quality-of-life scores were assessed by linear regression adjusting for the corresponding baseline values of each parameter. All analyses were conducted with Stata version 14.1 (StataCorp), and a 2-sided P<.05 was considered statistically significant.
Of 892 participants screened between August 17, 2016, and June 28, 2018, when the recruitment goal was reached, 465 fulfilled criteria for randomization. Excluding 1 participant who was erroneously randomized and did not receive study treatment, 464 participants, including 233 randomly assigned to enalapril and 231 assigned to sacubitril-valsartan, were included in the primary analysis (Figure). Study groups were well matched with regard to key baseline characteristics (Table 1). In the overall study population, the mean age was 67.3 (SD, 9.1) years, 109 (23.5%) were female, 115 (24.8%) were black, 313 (67.4%) reported New York Heart Association class II functional status, and 391 (84.3%) were previously treated with an ACE inhibitor or ARB.
During the double-blind treatment interval, study drug was discontinued in 17 (7.3%) participants assigned to enalapril and 16 (6.9%) assigned to sacubitril-valsartan. Successful titration to the target dosage was achieved in 199 (85.4%) participants assigned to enalapril and 192 (82.8%) assigned to sacubitril-valsartan. One patient in each group died and 1 in each group was lost to follow-up at 12 weeks.
Quiz Ref IDFrom baseline to 12 weeks, the primary end point of Zc decreased from 223.8 to 218.9 dyne × s/cm5 in the sacubitril-valsartan group and increased from 213.2 to 214.4 dyne × s/cm5 in the enalapril group. There was no statistically significant difference between groups in the change from baseline (between-group difference, −2.2 dyne × sec/cm5; 95% CI, −17.6 to 13.2 dyne × sec/cm5; P = .78), despite observed reduction in brachial systolic blood pressure by 6.4 mm Hg in the sacubitril-valsartan group and by 1.6 mm Hg in the enalapril group (between-group difference, −4.8 mm Hg; 95% CI, −7.6 to −2.1 mm Hg; P = .001) and in central systolic blood pressure by 4.9 mm Hg and 2.3 mm Hg, respectively (between-group difference, −2.6 mm Hg; 95% CI, −5.8 to 0.5 mm Hg; P = .10) in post hoc analyses (Table 2).
Quiz Ref IDGreater reductions from baseline were seen among participants assigned to sacubitril-valsartan compared with those assigned to enalapril in left ventricular end-diastolic volume index (from 75.1 to 70.3 mL/m2 with sacubitril-valsartan vs from 79.1 to 75.6 mL/m2 with enalapril; between-group difference, −2.0 mL/m2; 95% CI, −3.7 to −0.3 mL/m2; P = .02), left ventricular end-systolic volume index (from 50.8 to 46.3 mL/m2 with sacubitril-valsartan vs from 54.1 to 50.6 mL/m2 with enalapril; between-group difference, −1.6 mL/m2; 95% CI, −3.1 to −0.03 mL/m2; P = .045), left atrial volume index (from 30.4 to 28.2 mL/m2 with sacubitril-valsartan vs from 29.8 to 30.5 mL/m2 with enalapril; between-group difference, −2.8 mL/m2; 95% CI, −4.0 to −1.6 mL/m2; P < .001), and mitral E/e′ ratio (from 13.8 to 12.3 with sacubitril-valsartan vs from 13.4 to 13.8 with enalapril; between-group difference, −1.8; 95% CI, −2.8 to −0.8; P = .001) (Table 3). Although ejection fraction increased modestly by 1.9% in the sacubitril-valsartan group and by 1.3% in the enalapril group, we observed no significant between-group differences in change from baseline to 12 weeks in left ventricular ejection fraction (between-group difference, 0.6%; 95% CI, −0.4% to 1.7%; P = .24) or in other measured parameters, including global longitudinal strain, mitral e′ velocity, or Ea/Ees ratio (Table 3).
Levels of NT-proBNP, soluble ST2, and high-sensitivity troponin T were reduced to a greater extent at 12 weeks in the sacubitril-valsartan group than in the enalapril group, while the urinary cyclic guanosine monophosphate/urinary creatinine ratio was increased in the sacubitril-valsartan group (Table 4). In post hoc analyses, changes in NT-proBNP were significantly correlated with changes in left ventricular volume (eFigure in Supplement 2).
The KCCQ overall summary score improved by 8.9 points in the sacubitril-valsartan group and by 4.3 points in the enalapril group (between-group difference, 4.5 points; 95% CI, 1.7-7.3 points; P = .002). The proportion of patients experiencing improvement of 5 points or more in the KCCQ overall summary score was similarly higher in the sacubitril-valsartan group (58% vs 43%; P = .001). In a post hoc analysis, changes in quality of life were observed to be correlated with improvements in NT-proBNP (eFigure in Supplement 2).
Rates of hypotension (3.9% with sacubitril-valsartan vs 1.7% with enalapril), hyperkalemia (16.0% vs 12.9%, respectively), and worsening renal function (5.2% vs 6.0%, respectively) were similar in both treatment groups. One adjudicated episode of angioedema was noted in the enalapril group (eTable in Supplement 2).
In this randomized study of participants with HFrEF, ARNI therapy with sacubitril-valsartan did not reduce the primary study end point of Zc at 12 weeks relative to ACE inhibition with enalapril. Significant reductions were seen with sacubitril-valsartan in selected secondary echocardiographic end points, including left ventricular end-diastolic and end-systolic volumes, left atrial volume, and mitral E/e′ ratio, suggesting improvement in cardiac remodeling and estimated filling pressures, but no difference was noted in measures of contractile function (left ventricular ejection fraction, global longitudinal strain) or ventricular-vascular coupling (Ea/Ees ratio). The favorable cardiac structural changes paralleled reductions in NT-proBNP and improvements in overall quality of life assessed by the KCCQ overall summary score. These data suggest that clinical benefits of sacubitril-valsartan compared with enalapril in patients with HFrEF are likely unrelated to changes in central aortic stiffness or pulsatile load, despite favorable effects of neprilysin inhibition on myocardial remodeling and wall stress.
Central aortic stiffness is known to be increased in heart failure14 and is a key contributor to pulsatile load and wall stress in the left ventricle.8 Although composite ACE-neprilysin inhibition with omapatrilat has been shown to reduce Zc in patients with hypertension,4 a similar effect was not seen with ARNI in this HFrEF population. One possible explanation is that impedance was lower than anticipated at baseline,15 perhaps due to greater basal activation of the natriuretic peptide system in HFrEF (compared with hypertension), which may have lessened the effect of additional elaboration of vasoactive peptides with neprilysin inhibition. Alternatively, high levels of pretreatment with ACE inhibitors/ARBs (>80%) may have facilitated previous aortic remodeling and reduced the opportunity for additional improvement, even with effective medical therapy. It is also possible that 12 weeks was insufficient time to observe an aortic remodeling effect, and a reduction in Zc might have been apparent over longer-duration follow-up. The lack of reduction in Zc with neprilysin inhibition in this study does not obviate the possibility that other drugs might reduce aortic stiffness and Zc, with favorable effects on the failing heart. Nonetheless, these data suggest that substantial clinical benefits of neprilysin inhibition in HFrEF are likely not mediated through effects on aortic stiffness or pulsatile load.
In secondary analyses, treatment with sacubitril-valsartan was associated with improvements in atrial and ventricular remodeling, lower NT-proBNP, and lower Doppler-derived filling pressures. Although these changes were modest, they occurred earlier than typically observed after initiation of pharmacologic treatment, were observed in a population without advanced cardiac remodeling at baseline, and tracked with changes in cardiac biomarkers and measures of quality of life. Reduction in atrial and ventricular volumes in the absence of an observed effect on load, ejection fraction, or longitudinal strain suggests a possible acute effect on filling pressures, perhaps related to increased venous capacitance or natriuresis. This hypothesis is supported by early and sustained reductions in cardiac biomarkers of wall stress and injury that mirror changes previously observed in PARADIGM-HF6,16 and suggests that reduction in congestion or favorable remodeling effects, rather than changes in after-load or contractile function, may account for the early reductions in heart failure events with sacubitril-valsartan seen in recent trials.1,17
The potential clinical relevance of these early hemodynamic changes is illuminated by exploratory analyses suggesting robust and concordant improvements in quality of life. The observed between-group difference of 4.5 points in change from baseline to 12 weeks in the KCCQ overall summary score is greater than that reported at 8 months in PARADIGM-HF,18 in which quality-of-life questionnaires were administered after a run-in period during which all patients received sacubitril-valsartan and reflects a large proportion of participants with a clinically meaningful (≥5-point) improvement over time. Collectively, these data from a lower-risk heart failure sample provide additional support for current guideline directives to substitute ARNI for ACE inhibitors/ARBs even in the face of apparent clinical stability.
This study has several limitations. Quiz Ref IDFirst, randomized treatment exposure was limited to 12 weeks on ethical grounds because of the established benefits of ARNI over ACE inhibitors/ARBs in patients with HFrEF. It is possible that additional benefits on cardiovascular structure and function may have been apparent over a longer treatment duration, as was recently suggested in a small study of Korean patients with HFrEF and functional mitral regurgitation.19 Second, the study population reflects a mildly symptomatic HFrEF population without persistent atrial fibrillation, and results may not be generalizable to unselected patients with heart failure in clinical practice. Third, because this study was not powered to examine clinical outcomes, the contribution of observed changes in cardiac structure and biomarkers to clinical benefits observed in PARADIGM-HF cannot be directly assessed.
Among patients with heart failure and reduced ejection fraction, treatment with sacubitril-valsartan, compared with enalapril, did not significantly reduce central aortic stiffness. The study findings may provide insight into mechanisms underlying the effects of sacubitril-valsartan in HFrEF.
Corresponding Author: Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (firstname.lastname@example.org).
Accepted for Publication: August 6, 2019.
Published Online: September 2, 2019. doi:10.1001/jama.2019.12843
Author Contributions: Drs Desai and Claggett had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Desai, Solomon, Rocha, Mitchell.
Acquisition, analysis, or interpretation of data: Desai, Shah, Claggett, Fang, Izzo, McCague, Abbas, Mitchell.
Drafting of the manuscript: Desai, Claggett, Abbas.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Desai, Solomon, Claggett, McCague, Abbas.
Obtained funding: Solomon, Mitchell.
Administrative, technical, or material support: Abbas, Rocha, Mitchell.
Supervision: Desai, Solomon, Fang, Rocha, Mitchell.
Conflict of Interest Disclosures: Dr Desai reported receipt of research support from Alnylam, AstraZeneca, and Novartis and consulting fees from AstraZeneca, Abbott, Alnylam, Biofourmis, Boehringer Ingelheim, Boston Scientific, DalCor Pharma, Novartis, and Regeneron. Dr Solomon reported receipt of research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, the National Institutes of Health/National Heart, Lung, and Blood Institute, Novartis, Sanofi Pasteur, and Theracos and consulting for Akros, Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardior, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GlaxoSmithKline, Ironwood, Merck, MyoKardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AOBiome, Janssen, Cardiac Dimensions, and Tenaya. Dr Shah reported receipt of research support from Novartis, Gilead, and Actelion and consulting fees from Myocardia. Dr Claggett reported receipt of consulting fees from Gilead, MyoKardia, Corvia, AOBiome, and Boehringer Ingelheim. Dr Fang reported receipt of consulting fees from Amgen and Novartis. Dr Izzo reported receipt of research support from Novartis. Mr McCague, Dr Abbas, and Dr Rocha are employees of Novartis. Dr Mitchell is the president of Cardiovascular Engineering Inc, a company that designs and manufactures devices that measure vascular stiffness, and reported serving as a consultant to and receiving honoraria and grant support from Novartis, Servier, Merck, and the National Institutes of Health.
Funding/Support: This study was sponsored by Novartis.
Role of the Funder/Sponsor: The protocol, including the statistical analysis plan, was developed by the trial steering committee in collaboration with the sponsor. Data were collected, managed, and analyzed by the sponsor according to the predefined statistical analysis plan, and all analyses were verified by an independent academic statistician (Dr Claggett). The sponsor had the right to review the manuscript but did not have the right to veto publication or control the decision regarding to which journal the manuscript was submitted, and several individuals employed by the sponsor were coauthors of the manuscript who fulfilled authorship criteria. All decisions regarding publication of the study results were made by the academic steering committee and approved by all authors.
Group Information: EVALUATE-HF Investigators (listed in descending order according to number of patients randomized): Erie County Medical Center, Buffalo, New York: Joseph Izzo; Infinite Clinical Research, Doral, Florida: Melvin Martinez-Castrillon; Hi Tech and Global Research LLC, Coral Gables, Florida: Jorge Beato; Carolina Heart Specialists, Lancaster, South Carolina: Vipul Shah; Aventura Clinical Research, Aventura, Florida: Leonard Pianko; Elite Cardiac Research Center, Hialeah, Florida: Manuel Bouza; Research Associates of Jackson/Apex Cardiology, Jackson, Tennessee: Mohsin Alhaddad; Private Practice Leadership LLC, Houston, Texas: Amir Kashani; Clinical Trials of America, Minden, Louisiana: Gregory Sampognaro; Midwest Heart & Vascular Specialists LLC, Overland, Kansas: Lloyd Stahl; Medicoricium LLC, Fairview Heights, Illinois: John Lehman; Pharma Research International Inc, Naples, Florida: Steve Lebhar; Clinical Trials of America LA LLC, Monroe, Louisiana: Mark Napoli; Elite Clinical Research, Miami, Florida: Aurelio Torres Consuegra; Innovation Medical Research Center, Miami, Florida: Humberto Gonzalez; Cardiovascular Research Center of South Florida, Miami: Ramon Lloret; Valley Clinical Trials Inc, Northridge, California: Mehrdad Ariani, Masoud Azizad; Coastal Heart Medical Group, Santa Ana, California: Anil Shah; Cardiology Associates Research Co, Daytona Beach, Florida: David Henderson; Garden State Health Care, Manalapan, New Jersey: John Covalesky; PharmaTex Research, Amarillo, Texas: David Brabham; California Heart Specialists, Huntington Beach: Majed Chane; Cardiovascular & Vein Center of Florida, Bradenton: Eulogio Sanchez; Crystal Pharmacology Research, Miami, Florida: Ramses Vega; Cardiology Physicians PA, Newark, Delaware: Anthony Clay; Mid Michigan Heart and Vascular Center, Saginaw: John McClure; Georgia Arrhythmia Consultants, Macon, Georgia: Felix Sogade; SIMA Research Clinic, Miami, Florida: Luis Ortiz-Munoz; East Coast Institute for Research LLC, St Augustine, Florida: Todd Lewis; Celen Medical Group Corp, Miami, Florida: Argentina Gonzalez Zequeira; Bay Area Heart, Webster, Texas: Rakesh Shah; Westside Medical Associates of Los Angeles, Beverly Hills, California: Norman Lepor; Advance Research Center LLC, Miami, Florida: Marisela Gonzalez; River Birch Research Alliance LLC, Blue Ridge, Georgia: Raymond Tidman; Cardiology Associates of Fairfield County PC, Trumbull, Connecticut: Jeffrey Berman; Cardiology Associates of Fairfield County PC, Norwalk, Connecticut: David Lorenz; Cardiac Care & Vascular Medicine, Bronx, New York: Michele Nanna; East Coast Institute for Research, Jacksonville, Florida: Trevor Greene; Cardiology Associates of Fairfield County, Stamford, Connecticut: Edward Portnay; Louisiana Heart Center, Slidell: Marc Bernstein; Cordova Research Institute LLC, Miami, Florida: Guillermo Somodevilla; Detroit Clinical Research Center, Farmington Hills, Michigan: Robert Grodman; Gaffney Health Services, Charlotte, North Carolina: Mary Gaffney; Lakeland Cardiology Center PA, Mountain Lakes, New Jersey: Hyeun Park; Comprehensive Cardiovascular Care, Gurnee, Illinois: Isaac Dor; Northwest Houston Clinical Research PLLC, Tomball, Texas: Shamaila Aslam; Dominion Medical Associates Inc, Richmond, Virginia: Richard Jackson; BioMed Research Institute, Miami, Florida: Guido Perez; Universal Axon Clinical Research, Doral, Florida: Luis Martinez; Gandelman Cardiology, Greenwich, Connecticut: Glenn Gandelman; Clinical Trials of America–NC LLC, Lenoir, North Carolina: Johnny Dy; Endeavor Medical Research, Alpena, Michigan: Abraham Salacata; Nature Coast Clinical Research, Inverness, Florida: Rafik Abadier; Integrated Cardiology Group LLC dba Bryan Heart, Lincoln, Nebraska: John Steuter; M.A.R.C. Trials LLC, Little Rock, Arkansas: Sadeem Mahmood, Harold Betton; Research Integrity LLC, Owensboro, Kentucky: Kishor Vora; University of Alabama at Birmingham: Jose Tallaj; Atlantic Clinical Research Collaborative–Cardiology, Boynton Beach, Florida: Debra Weinstein; East Carolina Heart Institute, Greenville, North Carolina: Hassan Alhosaini; Kooental Heart Clinics, Coeur d’Alene, Illinois: John Everett; Heart and Vascular Center/Holy Family Memorial Inc, Manitowoc, Wisconsin: Michael Rosenberg; Augusta University, Clinical Trials Office, Augusta, Georgia: Stephanie Dunlap; Laurelton Heart Specialists PC, Rosedale, New York: Olakunle Akinboboy; NJ Heart, Linden, New Jersey: Jasjit Walia; Premier Cardiology Consultants, Lake Success, New York: Yuly Lyandres; Integrative Research Associates Inc, Fort Lauderdale, Florida: Barry Harris; CardioVoyage LLC, McKinney, Texas: Wael Abo-Auda; Horizon Research Group of Opelousas LLC, Eunice, Louisiana: Zebediah Stearns; Palm Research Center Inc, Las Vegas, Nevada: Navid Kazemi; Advanced Clinical Research Group, Stuart, Florida: Arden Bradley; Mid Columbia Research, Richland, Washington: Lucien Megna; CardioCare, Hillsborough, New Jersey: Jeff Taylor; The Heart & Vascular Clinic PA, Newark, Delaware: Anthony Innasimuthu; Kootenai Heart Clinics LLC, Spokane, Washington: L. Douglas Waggoner; Our Lady of the Lake Physician Group, Office of Research, Baton Rouge, Louisiana: Denzil Moraes; MedStar Heart and Vascular Institute, Baltimore, Maryland: Sandeep Jani; Cardiology Care Clinics, Eatonton, Georgia: Nicolas Chronos; Sherman Clinical Research, Sherman, Texas: Nikhil Joshi; Radin Cardiovascular Medical Associates, Newport Beach, California: Michael Radin; The Heartbeat Clinic PA, McKinney, Texas: Amer Suleman; Cardiology Consultants of Philadelphia, Yardley, Pennsylvania: Paul Grena; Athena Clinical Research LLC, Athens, Georgia: Subodh Agrawal; CHI Health Creighton University Medical Center–Bergan, Omaha, Nebraska: Mark Holmberg.
Meeting Presentation: This research was presented at the ESC Congress; September 2, 2019; Paris, France.
Data Sharing Statement: See Supplement 4.
Additional Contributions: We acknowledge Jessica Kachadourian, PharmD, a Novartis employee, for her contributions to the design, implementation, and execution of the EVALUATE-HF trial.
Create a personal account or sign in to: